Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Vacation home made with GreenCoat® steel nominated for highly recognized World Architecture Award (WAF) 2017

The House KD, a vacation home in Sweden featuring a GreenCoat® color coated steel roof, has been shortlisted for the 2017 World Architecture Festival (WAF) Award in the category “Villa - Completed Buildings”.Designed by architect Timo Karasalo, at GWSK Arkitekter in Stockholm, House KD is a year-round vacation home located on the island of Öland in Sweden. The WAF Award shortlisted house features design elements similar to traditional buildings on the island, but with modern and highly sustainable materials. The Metallic Silver roof of the House KD is made from GreenCoat® color coated

Holiday home made with GreenCoat® steel nominated for highly recognized World Architecture Award (WAF) 2017

The House KD, a holiday home in Sweden featuring a GreenCoat® colour coated steel roof, has been shortlisted for the 2017 World Architecture Festival (WAF) Award in the category “Villa - Completed Buildings”.Designed by architect Timo Karasalo, at GWSK Arkitekter in Stockholm, House KD is a year-round holiday home located on the island of Öland in Sweden. The WAF Award shortlisted house features design elements similar to traditional buildings on the island, but with modern and highly sustainable materials. The Metallic Silver roof of the House KD is made from GreenCoat® colour coated

RhoVac reports a positive meeting with the European Medicines Agency

RhoVac AB ("RhoVac") announced today, 26 October 2017 that the company has had a positive meeting with the European Medicines Agency ("EMA") regarding the regulatory development of the company's cancer vaccine RV001.RhoVac's therapeutic cancer vaccine RV001 is currently in clinical phase I/II focusing on patients with diagnosed prostate cancer. RV001 is developed with the goal of preventing or limiting the spread of cancer metastasis. Treatment with cancer vaccine RV001 is a targeted therapy against the RhoC protein. RhoC is over-expressed in almost all cancer cells that can metastasize -

#17-496 Recalculation of reference value for BULL NOKIA X8 CK

The reference value for BULL NOKIA X8 CK have been recalculated in accordance with the instruments final terms. The instrument will be traded under observation for the rest of the trading day.  For more information concerning the recalculations, please contact the issuers of the affected instruments. For further information concerning this NDX notice please contact: NGM market surveillance, +46 8 566 390 55, marketsurveillance@ngm.se Nordic Growth Market NGM ABAbout NDX Nordic derivatives Exchange (NDX) is a market for listing and trading of derivatives and other structured

Repo rate unchanged at −0.50 per cent

Economic activity is strong and inflation is close to the target of 2 per cent. Monetary policy needs to remain expansionary for inflation to continue to be close to 2 per cent. The Executive Board of the Riksbank has therefore decided to hold the repo rate unchanged at −0.50 per cent and is expecting, as before, not to raise it until the middle of 2018. The purchases of government bonds will continue during the second half of 2017, as decided by the Executive Board in April. As the present asset purchase programme will run for the remainder of the year, it will provide an opportunity to

The leaders of The Royal Swedish Academy of Sciences urges Iran to withdraw the death penalty of Ahmadreza Djalali

The Royal Swedish Academy of Sciences urges the Iranian government to withdraw the death penalty of Dr. Ahmadreza Djalali, an Iranian medical doctor, university lecturer, and researcher in disaster medicine, who has been detained in Evin Prison since April 2016 under harsh conditions.The leaders of The Royal Swedish Academy of Sciences considerDr. Djalali´s death sentence to be a threat of the independent and open research community. An open letter has been sent to President Hassan Rouhani and Ayatollah Sayed ‘Ali Khamenei. The letter is signed by Christina Moberg, President of the

Interim report January-September 2017

The Group delivered a varied performance during the quarter. Lesjöfors and Beijer Tech continued to display stable growth in volumes and earnings, while Habia reported a weaker trend.Generally speaking, demand was favorable in most geographic markets and industries. Lesjöfors’s Chassis Springs business area and Habia’s Telecom business area continued to report higher volumes and deliveries to the engineering industry than in the preceding year. Invoicing rose 5 percent to MSEK 880 (840) during the third quarter. Adjusted for exchange rates and corporate acquisitions, the increase was 4

Record increase in electricity from the forest

Between January and September, Södra delivered 15 times more green electricity to the public electricity grid compared with the same period in 2015. Deliveries are equivalent to the total electricity consumption* of 7,000 houses per year. The electricity is produced from the forest raw material that is processed at Södra’s mills.“We are very pleased with this substantial increase. It shows how we can use innovation and investments in green industry to meet important societal needs,” said Roine Morin, Sustainability Director at Södra. During 2017, Södra has delivered 15 times more

Publishing of Apetit Plc’s interim report for January-September 2017 and invitation to a briefing

Apetit Plc, Stock Exchange Release on 26[th] October, 2017 at 10:00 a.m. EET   Apetit Plc will publish its interim report for January-September 2017 on Thursday 2nd November 2017 at 8:30 a.m. Finnish time. A briefing (in Finnish) for analysts and media will be held on the same day at 10:00 a.m. in Hotel Scandic Simonkenttä, meeting room Espa, (address: Simonkatu 9, Helsinki). The presentation material will be also published on company web pages at apetitgroup.fi after the event. In the briefing Apetit Plc’s CEO Juha Vanhainen presents the third quarter interim report and gives

Notice of Extraordinary General Meeting in Inwido AB

The shareholders of Inwido AB (publ) are hereby invited to attend the Extraordinary General Meeting (“EGM”) to be held on Monday 20 November 2017 at 4.00 p.m. CET, at Inwido’s head office, Engelbrektsgatan 15 in Malmö. Registration of attendance commences at 3.45 p.m. The notice is available at www.inwido.com where shareholders also can notify the company of their intention to attend the EGM.Right to attendShareholders who wish to attend the EGM must: · be recorded in the share register for the company maintained by Euroclear Sweden AB, as of Tuesday 14 November 2017, and · notify

KONGSBERG contract with Lithuania for NASAMS air defence system worth 109 MEURO

Today KONGSBERG signed a contract worth 109 MEURO (approx. 1.000 MNOK) with the Ministry of National Defence of the Republic of Lithuania to supply a NASAMS air defence system.Lithuania announced 21 October 2016 an agreement with the Norwegian Ministry of Defence on procurement of NASAMS components; today’s contract includes new additional equipment, training and integrated logistics support package, as well as refurbishment and integration of government supplied components for a complete NASAMS system. “We are pleased that the Lithuanian Armed Forces has chosen NASAMS. NASAMS, produced

Senzime reports from the American Society of Anesthesiologists (ASA)

NEWS Uppsala, 26 October 2017. Senzime reports from the American Society of Anesthesiologists (ASA) Annual Meeting in Boston, USA.For more than 67 years, the ASA Annual Meeting has been the most comprehensive anesthesia-related educational event in the world, bringing together top influential and notable professionals in anesthesiology, pain medicine and critical care medicine. Numerous presenters discussed patient safety initiatives and necessary steps to reduce adverse events in the perioperative period. Professor Sorin J. Brull, MD from the Mayo Clinic and BOD member at Senzime,

Initiator Pharma initiates toxicology and toxicokinetic studies for its lead drug candidate IPED2015

Initiator Pharma A/S, a Danish Biotech Company developing a novel treatment of Erectile Dysfunction (ED), has initiated its first Good Laboratory Practice (GLP) toxicology and toxicokinetic rat study at Syngene, Bangalore, India. The decision to move forward with the first GLP study was based on the successful completion of preliminary dose range studies in rats and minipigs that as expected showed no critical adverse effect findings affecting the progress of the project. Furthermore, the start of the GLP study is also facilitated by the successful manufacturing of the GLP toxicological

Management changes in ComeOn

Jonas Wåhlander, Managing Director of ComeOn Malta Ltd has today stepped down from his position. A new management team with extensive experience is in charge of taking ComeOn! to the next level.“The integration process in our Online Gaming business area has reached a point where we now want to intensify our growth ambitions and further strengthen ComeOn!’s market position. Following a period of internal focus, it is time to take advantage of the strength that exists within the company. We have begun the recruitment of a new Managing Director for ComeOn! and the new management team comprises

Interim report, January – September 2017

Period July 1 – September 30, 2017 · Net sales SEK 88.0 m (SEK 83.2 m) · System revenue SEK 56.7 m (SEK 56.2 m) · Recurring revenue in percentage of net sales 57 % (54 %) · EBITDA SEK 22.1 m; 25.1 % (SEK 19.9 m; 23.9%) · EBITDA-adj. SEK 13.3 m; 15.1% (SEK 10.8 m; 13.0 %) · EBIT SEK 11.1 m; 12.7 % (SEK 6.2 m; 7.5 %) · Net profit SEK 6.5 m; 7.3 % (SEK 5.6 m; 6.7 %) · EPS before dilution SEK 0.12 (SEK 0.10) · Cash flow from operating activities SEK 16.9 m (SEK 9.0 m) Period January 1 – September 30, 2017 · Net sales SEK 279.8 m (SEK 272.0 m) · System

AAK’s Interim report for the third quarter 2017 – all-time high operating profit

· Operating profit reached SEK 475 million (431 excluding acquisition costs), an improvement of 10 percent. The currency translation impact was negative SEK 14 million of which SEK 9 million was related to Food Ingredients and SEK 5 million to Chocolate & Confectionery Fats. Operating profit at fixed foreign exchange rates and excluding acquisition costs improved by 13 percent. · Total volumes continued to grow nicely and increased by 8 percent (11). Organic volume growth was 4 percent (4). The demand for speciality and semi-speciality products continued to be strong and generated

ChromoGenics expands to Denmark and appoints Michael Felthaus to drive sales

Michael Felthaus has been appointed Business developer and will be responsible for sales in Denmark. This appointment reflects ChromoGenics’ strong ambition to expand its operations outside Sweden. Michael has a solid sales and business development background with more than 20 years of various positions within dynamic façade solutions in the glass as well as in the solar control industry. He has several years at WindowMaster, a part of VKR INWIDO/Art Andersen. “We are pleased to have Michael joining us to expand our business into Denmark. Michael brings proven successful sales

Interim Report Q2 1 April - 30 September 2017

SECOND QUARTER (1 JULY - 30 SEPTEMBER 2017) · Net sales increased by 14 percent and amounted to SEK 1,892 million (1,658). · Operating profit before amortisation of intangible non-current assets (EBITA) increased by 17 percent and amounted to SEK 213 million (183) corresponding to an EBITA margin of 11.2 percent (11.0).  · Operating profit increased by 16 percent and amounted to SEK 181 million (156) corresponding to an operating margin of 9.6 percent (9.4). · Profit after tax increased by 12 percent and amounted to SEK 135 million (121) and earnings per share before dilution

AstraZeneca report finds PreciseInhale ‘reduces the risk’ of failure when developing inhaled drugs

New research released by Astra Zeneca at the Association of Inhalation Toxicologists (AIT) Conference in Copenhagen, Denmark, October 26-27 shows that PreciseInhale can reduce risk and speed up drug development: “dose levels could be selected with confidence before moving into the toxicology study, reducing the risk…inherent with this class of drugs.”The report found that Inhalation Sciences’ labtech system PreciseInhale delivered results that make it safer and quicker for scientists to choose which candidate drugs to continue developing: “Using this data, dose levels could be selected with

MEDIVIR AB – INTERIM REPORT, JANUARY – SEPTEMBER 2017

Positive data reported across multiple clinical programsJuly - September Significant events during the quarter · Positive topline results from phase IIa osteoarthritis study showed disease-modifying benefit and an acceptable safety and tolerability in this patient population. · FDA accepted Medivir´s IND application for MIV-711, enabling clinical development in the US. · The exclusive rights to MIV-802 for Greater China were outlicensed to Ascletis. · Clinical study of birinapant in combination with KEYTRUDA® (pembrolizumab) in patients with treatment-refractory solid

Interim Report 1 January - 30 September 2017

Stockholm October 26, 2017THIRD QUARTER SUMMARY, JULY–SEPTEMBER 2017  · Net sales increased to SEK 534.5 m (467.1), representing growth of 14 per cent. · EBITA was SEK 24.3 m (39.6), corresponding to an EBITA margin of 4.5 per cent (8.5). · Operating profit was SEK 2.7 m (24.6), corresponding to an operating margin of 0.5 per cent (5.3). · Profit after tax was SEK 0.6 m (17.2). · Earnings per share after dilution were SEK 0.02 (0.57). · Cash flow from operating activities was SEK -78,7 m (-37.2). SUMMARY OF SIGNIFICANT EVENTS DURING THE THIRD QUARTER, JULY–SEPTEMBER

Interim report January – September 2017

Positive acknowledgements from customers lead to the launch of ConverLight™ in Denmark!Third quarter of 2017 · Net sales for the period amounted to SEK 3.3 (1.0) million. · Earnings for the period amounted to SEK -13.5 (-10.2) million, which corresponds to earnings per share of SEK -0.58 (-1.37). · During the quarter, ChromoGenics invoiced and completed deliveries of dynamic glass to the head office of the Swedish Energy Agency, an office within Saldeen Real Estate and the first partial delivery to Atrium Ljungberg’s project Gränbystaden in Uppsala. · ChromoGenics has

Skanska builds court- and office building in Sollentuna, Sweden, for about SEK 420 million

Skanska has signed a contract with the Swedish National Courts Administration to build new court- and office premises in Sollentuna, Sweden. In connection with the contract writing, the contract is transferred from the Swedish National Courts Administration to Vacse AB. The contract is worth about SEK 420M, which will be included in the Nordic order bookings for the fourth quarter 2017.The new building, which will contain courtrooms as well as offices and commercial premises, will be connected with existing Attunda District Court. The project comprises a gross area of about 17,000 square

STOREBRAND LIVSFORSIKRING AS – ROADSHOW AND MANDATE ANNOUNCEMENT

Storebrand Livsforsikring AS, rated BBB+ (positive) by S&P, has mandated Danske Bank and Nordea to arrange a series of fixed income investor meetings commencing on November 3rd. Following the investor roadshow, a NOK or SEK denominated 30y non call 5y (30NC5) Solvency II compliant Tier 2 bond issue may follow, subject to inter alia market conditions. The purpose of the contemplated bond issue is refinancing of existing debt, i.e. bonds callable in May 2018 (ISIN NO0010430713). Investor meetings: Oslo, November 3rd Helsinki and Stockholm, November 6th For further information,

There are no items matching the current filter
There are no more items matching the current filter
Back to top